Patents by Inventor Elizabeth A. Reap

Elizabeth A. Reap has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TC-83-derived alphavirus vectors, particles and methods
    Patent number: 10570416
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: February 25, 2020
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS
    Publication number: 20160348132
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
  • TC-83-derived alphavirus vectors, particles and methods
    Patent number: 9441247
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: September 13, 2016
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS
    Publication number: 20150299728
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: July 6, 2015
    Publication date: October 22, 2015
    Inventors: Jon O. RAYNER, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • TC-83-derived alphavirus vectors, particles and methods
    Patent number: 9079943
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 14, 2015
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS
    Publication number: 20140205629
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 24, 2014
    Applicant: AlphaVax, Inc.
    Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
  • TC-83-derived alphavirus vectors, particles and methods
    Patent number: 8709441
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: April 29, 2014
    Assignee: Alphavax, Inc.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • TC-83-Derived Alphavirus Vectors, Particles and Methods
    Publication number: 20110027306
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: July 6, 2010
    Publication date: February 3, 2011
    Applicant: AlphaVax, Inc.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Alpha virus-based cytomegalovirus vaccines
    Patent number: 7419674
    Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising alphavirus replicon RNAs, wherein a first replicon RNA comprises nucleic acid encoding cytomegalovirus pp65 and IE1 protein or immunogenic fragments thereof, and a second replicon RNA comprises nucleic acid encoding cytomegalovirus gB protein or an immunogenic fragment thereof, and wherein each of the two replicon RNAs is contained within a separate alphavirus replicon particle.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: September 2, 2008
    Assignee: Alpha Vax, Inc.
    Inventors: Jeffrey D. Chulay, Sergey Dryga, Elizabeth A. Reap, Robert A. Olmsted, John S. Morris
  • TC-83-derived alphavirus vectors, particles and methods
    Publication number: 20050266550
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Application
    Filed: May 18, 2005
    Publication date: December 1, 2005
    Applicant: Alphavax, Inc.
    Inventors: Jon Rayner, Jonathan Smith, Bolyn Hubby, Elizabeth Reap
  • Alpha virus-based cytomegalovirus vaccines
    Publication number: 20050054107
    Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising alphavirus replicon RNAs, wherein a first replicon RNA comprises nucleic acid encoding cytomegalovirus pp65 and IE1 protein or immunogenic fragments thereof, and a second replicon RNA comprises nucleic acid encoding cytomegalovirus gB protein or an immunogenic fragment thereof, and wherein each of the two replicon RNAs is contained within a separate alphavirus replicon particle.
    Type: Application
    Filed: July 8, 2004
    Publication date: March 10, 2005
    Inventors: Jeffrey Chulay, Sergey Dryga, Elizabeth Reap, Robert Olmsted, John Morris
  • Treatment of melanoma using N,N-dimethylglycine
    Patent number: 4994492
    Abstract: This invention relates to a method for inhibiting the metastasis or formation of a melanoma tumor by treating the patient with an effective amount of N,N-Dimethylglycine.
    Type: Grant
    Filed: January 9, 1989
    Date of Patent: February 19, 1991
    Assignee: Foodscience Corporation
    Inventors: Roger V. Kendall, John W. Lawson, Elizabeth A. Reap